Effect of Supplementation in Polycystic Ovary Syndrome Patients
Phase 3
Recruiting
- Conditions
- Polycystic ovarian syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT20220909055921N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 86
Inclusion Criteria
Patients with polycystic ovary syndrome according to the Rotterdam criteria
Age range from 18 to 45 years
Not following a special diet
Not addicted to alcohol or drug abuse
The patient should not be pregnant or breastfeeding
Exclusion Criteria
History of oophorectomy
Use of antidepressants
Use of weight loss or appetite suppressants
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does Spirulina supplementation modulate in PCOS patients to improve metabolic factors?
How does Spirulina compare to metformin and inositol in improving insulin resistance and lipid profiles in PCOS?
Which biomarkers predict response to Spirulina in PCOS patients with insulin resistance or hyperandrogenism?
What are the adverse events associated with Spirulina supplementation in phase III PCOS trials?
Are combination therapies of Spirulina with omega-3 or myo-inositol more effective than monotherapy in PCOS?